Breast Cancer: Basic and Clinical Research (Nov 2012)

Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy

  • Eugene R. Ahn,
  • Emilie Wang,
  • Stefan Glück

Journal volume & issue
Vol. 2012, no. 6
pp. 191 – 207

Abstract

Read online

No abstracts available.